Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab Combinations in R/R DLBCL
NCT05267054Phase 2Completed
- Sponsor
- BeiGene
- Start
- Apr 2022
- Primary completion
- Aug 2024
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of ociperlimab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by BeiGene. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and Recommended Phase 2 Dose of Ociperlimab at 21 days. Started Apr 2022; status: completed.
02
Drugs
ociperlimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05267054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267054.